1. Home
  2. ATYR vs LPA Comparison

ATYR vs LPA Comparison

Compare ATYR & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • LPA
  • Stock Information
  • Founded
  • ATYR 2005
  • LPA 2013
  • Country
  • ATYR United States
  • LPA United States
  • Employees
  • ATYR N/A
  • LPA N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • LPA
  • Sector
  • ATYR Health Care
  • LPA
  • Exchange
  • ATYR Nasdaq
  • LPA Nasdaq
  • Market Cap
  • ATYR 330.7M
  • LPA 310.7M
  • IPO Year
  • ATYR 2015
  • LPA N/A
  • Fundamental
  • Price
  • ATYR $3.68
  • LPA $9.20
  • Analyst Decision
  • ATYR Strong Buy
  • LPA
  • Analyst Count
  • ATYR 6
  • LPA 0
  • Target Price
  • ATYR $18.60
  • LPA N/A
  • AVG Volume (30 Days)
  • ATYR 1.9M
  • LPA 6.9K
  • Earning Date
  • ATYR 03-13-2025
  • LPA 03-25-2025
  • Dividend Yield
  • ATYR N/A
  • LPA N/A
  • EPS Growth
  • ATYR N/A
  • LPA N/A
  • EPS
  • ATYR N/A
  • LPA N/A
  • Revenue
  • ATYR $235,000.00
  • LPA $44,311,428.00
  • Revenue This Year
  • ATYR $1,387.23
  • LPA N/A
  • Revenue Next Year
  • ATYR $873.22
  • LPA N/A
  • P/E Ratio
  • ATYR N/A
  • LPA N/A
  • Revenue Growth
  • ATYR N/A
  • LPA 22.46
  • 52 Week Low
  • ATYR $1.42
  • LPA $6.00
  • 52 Week High
  • ATYR $4.66
  • LPA $525.00
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 50.20
  • LPA N/A
  • Support Level
  • ATYR $2.98
  • LPA N/A
  • Resistance Level
  • ATYR $4.32
  • LPA N/A
  • Average True Range (ATR)
  • ATYR 0.36
  • LPA 0.00
  • MACD
  • ATYR 0.03
  • LPA 0.00
  • Stochastic Oscillator
  • ATYR 60.37
  • LPA 0.00

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

Share on Social Networks: